New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 9, 2012
11:21 EDTMMM, SMI, PEG, MRO, KGC, ISIS, HRZN, FLT, ETP, CXO, OZRK, ATK, SBUXOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: 3M Company (MMM) upgraded to Neutral from Reduce at Nomura... Alliant Techsystems (ATK) upgraded to Buy from Neutral at Goldman... Bank of the Ozarks (OZRK) upgraded to Buy from Neutral at Sterne Agee... Concho Resources (CXO) upgraded to Buy from Hold at Stifel Nicolaus... Energy Transfer Partners (ETP) upgraded to Equal Weight at Morgan Stanley... FleetCor (FLT) upgraded to Buy from Neutral at Citigroup... Horizon Technology (HRZN) upgraded to Buy from Hold at Gilford Securities... Isis Pharmaceuticals (ISIS) upgraded to Outperform from Neutral at Cowen... Kinross Gold (KGC) upgraded to Outperform from Neutral at Macquarie... Marathon Oil (MRO) upgraded to Overweight from Neutral at JPMorgan.... PSEG (PEG) upgraded to Hold from Sell at ISI Group... Semiconductor Manufacturing (SMI) upgraded to Market Perform at Bernstein... Starbucks (SBUX) upgraded to Buy from Hold at Argus.
News For MMM;ATK;OZRK;CXO;ETP;FLT;HRZN;ISIS;KGC;MRO;PEG;SMI;SBUX From The Last 14 Days
Check below for free stories on MMM;ATK;OZRK;CXO;ETP;FLT;HRZN;ISIS;KGC;MRO;PEG;SMI;SBUX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
14:09 EDTATKATK spinoff, deal positive, says Argus
Subscribe for More Information
07:23 EDTMRO, ETPHart Energy to hold a conference
2014 DUG Eagle Ford Conference to be held in San Antonio, California on September 15-17.
September 14, 2014
13:35 EDTSBUXStarbucks shares could fall, Barron's says
Starbucks shares could fall and were placed on Hedgeye Risk Management analyst Howard Penney's best-ideas list as a short, Barron's argues in its 'The Trader' column. Reference Link
September 12, 2014
08:17 EDTSBUXStarbucks 6.2M share Block Trade priced at $75.15
BofA/Merrill acted as sole book running manager for the offering.
September 11, 2014
06:36 EDTSBUXStarbucks to sell single-origin coffees in supermarkets, WSJ reports
Subscribe for More Information
September 10, 2014
05:46 EDTETPEnergy Transfer Partners reinstated with an Overweight at Barclays
Subscribe for More Information
September 9, 2014
13:58 EDTSBUXStarbucks, Groupon, OpenTable apps among those to integrate Apple Pay
Subscribe for More Information
10:18 EDTETPDollar General listed among 5 largest long positions by Jana Partners
Subscribe for More Information
10:10 EDTMROOn the Fly: Analyst Upgrade Summary
Subscribe for More Information
09:08 EDTMROMarathon Oil upgraded to Buy from Accumulate at Tudor Pickering
08:46 EDTFLTGoldman to hold a conference
Subscribe for More Information
September 8, 2014
07:33 EDTMROMarathon Oil price target raised to $50 from $45 at Oppenheimer
Subscribe for More Information
September 5, 2014
06:04 EDTSBUXStarbucks accelerates growth of multiple diversified store formats
Subscribe for More Information
05:50 EDTKGCStocks with implied volatility movement; NUGT KGC
Subscribe for More Information
September 3, 2014
09:17 EDTMROMarathon Oil sees future drilling inventory increased to 4,650 net wells
Subscribe for More Information
08:09 EDTPEGPSEG repeats view of FY14 operating EPS at upper end of $2.55-$2.75
Subscribe for More Information
September 2, 2014
19:28 EDTISISIsis Pharmaceutical licensing partner Antisense reports ATL1103 phase II results
Antisense Therapeutics, or ANP, reported the primary efficacy results from its phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly. The phase II trial met its primary efficacy endpoint showing a statistically significant average reduction in the serum insulin-like growth factor-I, or sIGF-1, levels of 26% from baseline at week 14 at the 400mg per week dose tested. All patients treated with 400mg per week of ATL1103 had a reduction in sIGF-I levels from baseline at week 14. Greater reductions in sIGF-I were observed in patients who had lower body weights and thereby received a relatively higher dose per kg bodyweight with the patients who received 5.5 mg/kg per week showing a 36% average reduction in their sIGF-I levels. The positive results achieved in this Phase II trial position ATL1103 to move into Phase III stage of development. Consequently, ANP will accelerate out-licencing activities to secure a pharmaceutical development partner for the drug's further development. ANP has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals, including ATL1103.
08:37 EDTCXOConcho Resources price target raised to $170 from $115 at Stifel
Subscribe for More Information
07:08 EDTETPEnergy Transfer Partners reinstated with a Neutral at Credit Suisse
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use